摘要
目的:探讨托拉塞米治疗终末期肥厚型非梗阻性心肌病的临床疗效和安全性。方法:对52例终末期肥厚型非梗阻性心肌病患者用托拉塞米(托拉塞米组)和呋噻米(对照组)治疗10d。将体重、水肿程度、心功能分级、B型钠尿肽、血管紧张素Ⅱ、血钾、血钠、血氯含量等作为评价指标。结果:治疗10d后,托拉塞米组和对照组的心功能有显著改善,两组比较差异有统计学意义(P<0.01)。两组治疗前后的血钾、血钠、血氯等指标无明显变化。托拉塞米组和对照组的不良反应发生率分别为14.8%和24.0%,两组比较差异有统计学意义(P<0.01)。结论:每天1次静脉注射托拉塞米40mg治疗终末期肥厚型非梗阻性心肌病患者,能够显著改善心脏功能,效果明显优于呋噻米,且安全性较高。
Objective：To evaluate the validity and safety of torasemide in end-stage hypertrophic non-obstructive cardiomyopathy.Method：Torasemide or frusemide was administered by intravenous injection in 52 subjects with end-stage hypertrophic non-obstructive cardiomyopathy.Body weight,edema,NYHA class,brain natriuretic peptide,Angiotensin Ⅱ,blood potassium,sodium,chloride and others were evaluated.Result：After 10 days of treatment,there was improvement in cardiac function in both torasemide and control groups.However,cardiac function improvment in the torasemide group was more significant than in the furosemide group.There was no difference in the measured blood levels of potassium,sodium,chloride and others before and after administration.The incidence of adverse reaction was 14.8% and 24.0%,respectively in torasemide group and control group.Conclusion：Torasemide 40 mgper day administered by intravenous injection results in better improvement of cardiac function in patients with end-stage hypertrophic non-obstructive cardiomyopathy.Torasemide is a more effective and safe drug in treatment of hypertrophic non-obstructive cardiomyopathy（end-stage）than frusemide.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2016年第2期127-130,共4页
Journal of Clinical Cardiology
关键词
托拉塞米
心肌病
肥厚型非梗阻性
疗效
安全性
torasemide
cardiomyopathy
hypertrophic non-obstructive
validity
safety
